Unaltered hepatic oxidative phosphorylation and mitochondrial permeability transition in Wistar rats treated with nimesulide: Relevance for nimesulide toxicity characterization

Journal of Biochemical and Molecular Toxicology

Volumn 21, Issue 2, 2007, Pages 53-61

  Moreno, António J ^a   Oliveira, Paulo J ^b   Nova, Carlos D ^c   Álvaro, Ana R ^b   Moreira, Renata A ^c   Santos, Sandra M D ^c   Macedo, Tice ^c  

^a UNIVERSITY OF COIMBRA   (Portugal)

^b UNIVERSITY OF COIMBRA   (Portugal)

^c UNIVERSITY OF COIMBRA   (Portugal)

Author keywords

Liver mitochondria; Mitochondrial permeability transition; Nimesulide; Oxidative phosphorylation; Wistar rat

Indexed keywords

CALCIUM; CYCLOOXYGENASE 2 INHIBITOR; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; FEMALE; LIVER METABOLISM; LIVER MITOCHONDRION; LIVER TOXICITY; MALE; MEMBRANE POTENTIAL; MITOCHONDRIAL PERMEABILITY; MITOCHONDRIAL RESPIRATION; NONHUMAN; OXIDATIVE PHOSPHORYLATION; RAT; TOXICITY TESTING; TREATMENT DURATION; WISTAR RAT;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CALCIUM; CELL MEMBRANE PERMEABILITY; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; LIVER; MALE; MEMBRANE POTENTIAL, MITOCHONDRIAL; MITOCHONDRIA, LIVER; OXIDATIVE PHOSPHORYLATION; OXYGEN CONSUMPTION; RATS; RATS, WISTAR; SULFONAMIDES;

ANIMALIA; RATTUS; RATTUS NORVEGICUS;

EID: 34247399590     PISSN: 10956670     EISSN: 10990461     Source Type: Journal    
DOI: 10.1002/jbt.20159     Document Type: Article

References (45)

1. Rainsford KD. An analysis from clinico-epidemiological data of the principal adverse events from the COX-2 selective NSAID, nimesulide, with particular reference to hepatic injury. Inflammopharmacology 1998;6:203-221.
2. Traversa G, Bianchi C, Da Cas R, Abraha I, Menniti-Ippolito F, Venegoni M. Cohort study of hepatotoxicity associated with nimesulide and other non-steroidal antiinflammatory drugs. BMJ 2003;327:18-22.
3. Fossaluzza V, Montagnani G. Efficacy and tolerability of nimesulide in elderly patients with osteoarthritis: double-blind trial versus naproxen. J Int Med Res 1989;17:295-303.
4. Pasquale G, Scaricabarozzi I, D'Agostino R, Taborelli G, Vallarino R. An assessment of the efficacy and tolerability of nimesulide vs paracetamol in children after adenoton-sillectomy. Drugs 1993;46(suppl 1):234-237.
5. Weiss P, Mouallem M, Bruck R, Hassin D, Tanay A, Brickman CM, Farfel Z, Bar-Meir S. Nimesulide-induced hepatitis and acute liver failure. Isr Med Assoc J 1999;1:89-91.
6. Sbeit W, Krivoy N, Shiller M, Farah R, Cohen HI, Struminger L, Reshef R. Nimesulide-induced acute hepatitis. Ann Pharmacother 2001;35:1049-1051.
7. Van Steenbergen W, Peeters P, De Bondt J, Staessen D, Buscher H, Laporta T, Roskams T, Desnet V. Nimesulide-induced acute hepatitis: evidence from six cases. J Hepatol 1998;29:135-141.
8. Grignola JC, Arias L, Rondán M, Solá L, Bagnulo. Hepatoxicity associated with nimesulide. Arch Med Int 1998;20:13-18.
9. Merlani G, Oehen HP, Cathomas G, Renner EL, Fox M, Fattinger K, Schneemann M, Kullak-Ublick GA. Fatal hepatoxicity secondary to nimesulide. Eur J Clin Pharmacol 2001;57:321-326.
10. Davis R, Brogden RN. Nimesulide: an update of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs 1994;48:431-454.
11. Zimmerman HJ. Update of hepatotoxicity due to classes of drugs in common clinical use: non-steroidal drugs, anti-inflammatory drugs, antibiotics, antihypertensives, and cardiac and psychotropic agents. Semin Liver Dis 1990;10:322-338.
12. Robin MA, Le Roy M, Descatoire V, Pessayre D. Plasma membrane cytochromes P450 as neoantigens and autoimmune targets in drug-induced hepatitis. J Hepatol 1997;26(suppl 1):23-30.
13. Rainsford KD, Seabrook RW, Spencer S, Hewson AT. Effects of nimesulide and its metabolites or manufacturing intermediates on the viability and growth of the human hepatoma HepG2 cell line. Life Sci 2001;69:2965-2973.
14. Wallace KB, Starkov, AA. Mitochondrial targets of drug toxicity. Annu Rev Pharmacol Toxicol 2000;40:353-388.
15. Chan K, Truong D, Shangari N, O'Brien PJ. Drug-induced mitochondrial toxicity. Expert Opin Drug Metab Toxicol. 2005;1(4):655-669.
16. Caparroz-Assef SM, Bernani-Amado CA, do Nascimento EA, Kelmer-Bracht AM, Ishii-Iwamoto EL. Effects of the nonsteroidal anti-inflammatory drug nimesulide on energy metabolism in livers from adjuvant-induced arthritic rats. Res Commun Mol Pathol Pharmacol 1998;99:93-116.
17. Moreno-Sanchez R, Bravo C, Vasquez C, Ayala G, Silveira LH, Martinez-Lavin M. Inhibition and uncoupling of oxidative phosphorylation by nonsteroidal anti-inflammatory drugs: study in mitochondria, submitochondrial particles, cells, and whole heart. Biochem Pharmacol 1999;57:743-752.
18. Mingatto FE, dos Santos AC, Rodrigues T, Pigoso AA, Uyemura SA, Curti C. Effects of nimesulide and its reduced metabolite on mitochondria. Br J Pharmacol 2000;131:1154-1160.
19. Caparroz-Assef SM, Salgueiro-Pagadigorria CL, Bersani-Amado CA, Bracht A, Kelmer-Bracht AM, Ishii-Iwamoto EL. The uncoupling effect of the nonsteroidal anti-inflammatory drug nimesulide in liver mitochondria from adjuvant-induced arthritic rats. Cell Biochem Funct 2001;129:117-124.
20. Mingatto FE, Rodrigues T, Pigoso AA, Uyemura SA, Curti C, Santos AC. The critical role of mitochondrial energetic impairment in the toxicity of nimesulide to hepatocytes. J Pharmacol Exp Ther 2002;303:601-607.
21. Zoratti M, Szabo I. The mitochondrial permeability transition. Biochim Biophys Acta 1995;1241:139-176.
22. Kowaltowski AJ, Vercesi AE. Mitochondrial damage induced by conditions of oxidative stress. Free Radical Biol Med 1999;26:463-471.
23. Vieira HLA, Kroemer G. Pathophysiology of mitochondrial cell death control. Cell Mol Life Sci 1999;56:971-976.
24. Tay VKS, Wang AS, Leow KY, Ong MMK, Wong KP, Boelsterli UA. Mitochondrial permeability transition as a source of superoxide anion induced by the nitroaromatic drug nimesulide in vitro. Free Radical Biol Med 2005;39:949-959.
25. Bernareggi A. Clinical pharmacokinetics and metabolism of nimesulide Inflammopharmacology 2001;9:81-89.
26. 2+ and inorganic phosphate. Toxicol Appl Pharmacol 1998;152:10-17.
27. Estabrook R. Mitochondrial respiratory control and polarographic measurement of ADP:O ratios. Methods Enzymol 1967;X:41-57.
28. Kamo N, Muratsugu M, Hongoh R, Kobatake Y. Membrane potential of mitochondria measured with an electrode sensitive to tetraphenyl phosphonium and relationship between proton electrochemical potential and phosphorylation potential in steady state. J Membr Biol 1979;49:105-121.
29. Moreno AJM, Madeira VMC. Mitochondrial bioenergetics as affected by DDT. Biochim Biophys Acta 1991;1060:166-174.
30. Broekemeier K, Dempsey M, Pfeiffer D. Cyclosporin A is a potent inhibitor of the inner membrane mitochondrial transition in liver mitochondria. J Biol Chem 1989;264:7826-7830.
31. Boelsterli U. Mechanisms of NSAID-induced hepatotoxicity: focus on nimesulide. Drug Safety 2002;25:633-648.
32. Wallace JL. Nonsteroidal anti-inflammatory drugs and gastroenteropathy: the second hundred years. Gastroenterology 1997;112:1000-1006.
33. Elson CO, Sartor BR, Tennyson GS, Riddell RH. Experimental models of inflammatory bowel disease. Gastroenterology 1995;109:1344-1367.
34. Oliveira PJ, Bjork JA, Santos MS, Leino RL, Froberg MK, Moreno AJ, Wallace KB. Carvedilol-mediated antioxidant protection against doxorubicin-induced cardiac mitochondrial toxicity. Toxicol Appl Phamacol 2004;200:159-168.
35. Bernareggi A. Clinical pharmacokinetics of nimesulide. Clin Pharmacokinet 1998;35:247-274.
36. Rainsford KD. Nimesulide - a multifactorial approach to inflammation and pain: scientific and clinical consensus. Curr Med Res Opin 2006;22:1161-1170.
37. Hull ML, Prentice A, Wang DY, Wang RP, Butt RP, Phillips SC, Smith SK, Charnock-Jones DS. Nimesulide, a COX-2 inhibitor, does not reduce lesion size or number in nude mouse model of endometriosis. Hum Reprod 2005;20:350-358.
38. Gupta SK, Velpandim T, Mathur P, Sengupta S. Comparative analgesic activity of nimesulide and diclofenac by intramuscular route: correlation with pharmacokinetic profile of nimesulide. Pharmacology 1998;56:137-143.
39. Nieminen A-L, Saylor AK, Tesfai SA, Herman B, Lemasters JJ. Contribution of the mitochondrial permeability transition to lethal injury after exposure of hepatocytes to t-butylhydroperoxide. Biochem J 1995;307:99-106.
40. 2+ cycling in cytotoxicity. Biochem Pharmacol 1992;44:1995-2003.
41. Lemasters JJ, Nieminen AL, Qian T, Trost LC, Elmore SP, Nishimura Y, Crowe RA, Caseio WE, Bradham CA, Brenner DA, Herman B. The mitochondrial permeability transition in cell death: a common mechanism in necrosis, apoptosis and autophagy. Biochim Biophys Acta 1998;1366:177-196.
42. Berson A, Wolf C, Berger V, Fau D, Chachaty C, Fromenty B, Pessayre D. Generation of free radicals during the reductive metabolism of the nitroaromatic compound, nilutamide. J Pharmacol Exp Ther 1991;257:714-719.
43. 2+ ions. A proposed model for phosphate-stimulated lipid peroxidation. J Biol Chem 1996;271:2929-2934.
44. Berson A, Cazanave S, Descatoire V, Tinel M, Grodet A, Wolf C, Feldmann G, Pessayre D. The anti-inflammatory drug, nimesulide (4-nitro-2-phenoxymethane- sulfoanilide), uncouples mitochondria and induces mitochondrial permeability transition in human hepatoma cells: protection by albumin. J Pharmacol Exp Ther 2006;318:444-454.
45. Santos DL, Moreno AJM, Leino RL, Froberg MK, Wallace KB. Carvedilol protects against doxorubicin-induced mitochondrial cardiomyopathy. Toxicol Appl Pharmacol 2002;185:218-227.